MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: ALS

ALS

Latest news

Tag

Neurology

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy

A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.

Apr 22, 2026
Neurology

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st

Mar 30, 2026Sign in to read
Neurology

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.

Mar 18, 2026
Neurology

Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS Pathogenesis

This study identifies somatic gene mutations in excitatory neurons of the motor cortex as a potential driver of sporadic ALS, challenging the traditional view of the disease’s genetic origins.

Mar 12, 2026Sign in to read
Clinical Updates

Purine Biosynthetic Enzyme PAICS as a Central Mediator of DNA Damage and Cerebellar Atrophy in C9orf72-ALS

This review synthesizes recent evidence identifying PAICS downregulation as a critical link between C9orf72 loss-of-function, DNA repair failure, and cerebellar neurodegeneration, highlighting its potential as a therapeutic target.

Mar 11, 2026Sign in to read
Allergy & Immunology

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS

A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad

Dec 31, 2025
Allergy & Immunology

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Dec 6, 2025
Medical News

Blood Test Breakthrough: Detecting ALS Over a Decade Before Symptoms Emerge

New research identifies a protein signature in blood that detects ALS years before symptoms, challenging previous perceptions and offering hope for early diagnosis and intervention.

Sep 4, 2025
Clinical Updates

Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial

Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.

Aug 3, 2025
Neurology

Breakthrough Alert! The Dawn of a New ALS Treatment Era—Pioneering Injection Administered at Peking University Third Hospital

A study reveals that negative online comments significantly increase anxiety and lower mood, especially in younger adults. Digital literacy, self-care, supportive communities, and platform moderation are vital to mitigate these effects. Add

Jul 24, 2025
MMedXY
News

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story